Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 52 min ago
Peer-reviewedCC BY-NC 4.0BMJ Open

Establishing a national platform to facilitate patient recruitment and advanced diagnostics for cancer immunotherapies (the NHS Cancer Vaccine Launch Pad): a multicentre prospective cohort feasibility study protocol

15 more authors
12 affiliations
  1. 1Cancer Research UK Southampton Clinical Trials Unit, University of Southampton, Southampton, UK
  2. 2Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  3. 3University Hospital Southampton NHS Foundation Trust, Southampton, UK
  4. 4Faculty of Medicine, University of Southampton, Southampton, UK
  5. 5NHS England, London, UK
  6. 6Royal Free London NHS Foundation Trust, London, UK
  7. 7NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
  8. 8Department of Oncology, University of Oxford, Oxford, UK
  9. 9Oxford University Hospitals NHS Foundation Trust, Oxford, UK
  10. 10BC Platforms Ltd Oy, Espoo, Finland
  11. 11Clinical Informatics Research Unit, University of Southampton, Southampton, UK
  12. 12GenQA, Laboratory Medicine, NHS Lothian, Royal Infirmary of Edinburgh, Edinburgh, UK

Abstract

Background: The National Health Service (NHS) Cancer Vaccine Launch Pad (CVLP) is a research study designed to develop national patient referral and tumour tissue processing pathways to support patients with cancer to access commercial cancer vaccine and other targeted immunotherapy clinical trials. Recent advances in nucleic acid technology, tumour sequencing and immuno-oncology have renewed interest in cancer vaccines and other targeted immunotherapies. The CVLP aims to accelerate translation to routine care by assessing the feasibility of integrating patient screening, consent, biological sample handling and genomic profiling across the NHS to support access to these trials. This will prepare the NHS for wider implementation should these novel therapeutics be adopted.

Methods and analysis: The CVLP (ISRCTN13053675) is a multicentre prospective observational cohort feasibility study, sponsored by NHS England and coordinated by the Cancer Research UK Southampton Clinical Trials Unit (SCTU). Via an academically led protocol, adult participants will be recruited from participating NHS locations. Consent will be obtained for the use of routinely collected demographic and clinical data alongside access to surplus tumour tissue and other biological samples for molecular analysis. This will serve to guide trial eligibility and onward referral to commercial trials open in the UK. Initial feasibility of the CVLP platform will be assessed via recruitment rates, timeliness of tumour tissue and biological sample handling and the proportion of participants referred onward to commercial clinical trials on the CVLP portfolio. Analysis will be descriptive, summarising recruitment metrics, pathway timelines and follow-up outcomes.

Ethics and dissemination: This study received ethical approval from East of England—Essex Research Ethics Committee on 20 August 2023 (23/EE/0178). Findings will be disseminated through peer-reviewed publications, scientific meetings and stakeholder reports to inform national delivery models for NHS cancer services. Lay summaries of study progress and findings will be published on the SCTU website.

Trial registration number: ISRCTN13053675.

Related

  1. How Can We Reach You? An Overview of Establishing Effective Recruitment Strategies for Young Women Breast Cancer Survivors.
    Pearman D Parker, Tiffany A Bogan, Traci A Owen +1
    Cancer care research onlinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Predictability of symptom changes following hemithyroidectomy due to compression symptoms assessed by specific questionnaires: prospective multicentre study.
    Ervin Beka, Ivan Shabo, David Fornander +2
    BJS openPeer-reviewedCC BY-NCFull textSurgery & anaesthesiaEurope PMC
  3. Vibroacoustic lung therapy and early postoperative oxygenation after cardiac surgery: a multicentre prospective study
    Timur Kapyshev, Marat Shoranov, Zhangeldi Kadirov +5
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Safety and efficiency of the HEART-GP strategy with point-of-care high-sensitivity troponin testing for acute chest pain in out-of-hours primary care: a prospective multicentre diagnostic accuracy study
    I. Melessen, J. C. L. Himmelreich, A. Manten +2
    medRxivPreprintAll rights reservedFull textCardiovascular medicinemedRxiv
  5. Evaluation of the Efficacy and Safety of Combination Therapy of Vamha and Myrha in the Management of PMOS: An Open-Label, Randomized, Multicentre, Comparative, Prospective Clinical Study
    A. Patil, R. Barathe, D. M. Tate +7
    medRxivPreprintAll rights reservedFull textObstetrics, gynaecology & paediatricsmedRxiv
BibTeX
@article{moxleywyles2026establishing,
  title = {{Establishing a national platform to facilitate patient recruitment and advanced diagnostics for cancer immunotherapies (the NHS Cancer Vaccine Launch Pad): a multicentre prospective cohort feasibility study protocol}},
  author = {Benjamin Moxley-Wyles and Nicole Keyworth and Victoria M Goss and Samuel Goode and Laura Pope and Tiffany Joyce and Jeny Mathew and Charlotte M Stuart and Sarah Chamberlain and Jessica Curtis and Dan Muller and Emily C Shaw and Max Shen and Nicola Chapman-Hart and Molly Obadiah and Patrick Ezeani and Gillian Rosenberg and Jane Starczynski and Sarrah Tayabali and Katrina Cathie and Lennard YW Lee and Pivi Tikka-Kleemola and James Batchelor and Zandra C Deans and Simon Crabb and Gareth Griffiths and Peter WM Johnson},
  journal = {BMJ Open},
  year = {2026},
  month = nov,
  doi = {10.1136/bmjopen-2026-124300},
  url = {https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-124300},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Establishing a national platform to facilitate patient recruitment and advanced diagnostics for cancer immunotherapies (the NHS Cancer Vaccine Launch Pad): a multicentre prospective cohort feasibility study protocol
AU  - Benjamin Moxley-Wyles
AU  - Nicole Keyworth
AU  - Victoria M Goss
AU  - Samuel Goode
AU  - Laura Pope
AU  - Tiffany Joyce
AU  - Jeny Mathew
AU  - Charlotte M Stuart
AU  - Sarah Chamberlain
AU  - Jessica Curtis
AU  - Dan Muller
AU  - Emily C Shaw
AU  - Max Shen
AU  - Nicola Chapman-Hart
AU  - Molly Obadiah
AU  - Patrick Ezeani
AU  - Gillian Rosenberg
AU  - Jane Starczynski
AU  - Sarrah Tayabali
AU  - Katrina Cathie
AU  - Lennard YW Lee
AU  - Pivi Tikka-Kleemola
AU  - James Batchelor
AU  - Zandra C Deans
AU  - Simon Crabb
AU  - Gareth Griffiths
AU  - Peter WM Johnson
PY  - 2026
DA  - 2026/11/09
JO  - BMJ Open
DO  - 10.1136/bmjopen-2026-124300
UR  - https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2026-124300
AB  - Background: The National Health Service (NHS) Cancer Vaccine Launch Pad (CVLP) is a research study designed to develop national patient referral and tumour tissue processing pathways to support patients with cancer to access commercial cancer vaccine and other targeted immunotherapy clinical trials. Recent advances in nucleic acid technology, tumour sequencing and immuno-oncology have renewed interest in cancer vaccines and other targeted immunotherapies. The CVLP aims to accelerate translation to routine care by assessing the feasibility of integrating patient screening, consent, biological sample handling and genomic profiling across the NHS to support access to these trials. This will prepare the NHS for wider implementation should these novel therapeutics be adopted.  Methods and analysis: The CVLP (ISRCTN13053675) is a multicentre prospective observational cohort feasibility study, sponsored by NHS England and coordinated by the Cancer Research UK Southampton Clinical Trials Unit (SCTU). Via an academically led protocol, adult participants will be recruited from participating NHS locations. Consent will be obtained for the use of routinely collected demographic and clinical data alongside access to surplus tumour tissue and other biological samples for molecular analysis. This will serve to guide trial eligibility and onward referral to commercial trials open in the UK. Initial feasibility of the CVLP platform will be assessed via recruitment rates, timeliness of tumour tissue and biological sample handling and the proportion of participants referred onward to commercial clinical trials on the CVLP portfolio. Analysis will be descriptive, summarising recruitment metrics, pathway timelines and follow-up outcomes.  Ethics and dissemination: This study received ethical approval from East of England—Essex Research Ethics Committee on 20 August 2023 (23/EE/0178). Findings will be disseminated through peer-reviewed publications, scientific meetings and stakeholder reports to inform national delivery models for NHS cancer services. Lay summaries of study progress and findings will be published on the SCTU website.  Trial registration number: ISRCTN13053675.
SN  - 2044-6055
SN  - 2044-6055
ER  -